Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Predictors of Antidepressant Treatment Response: The Emory CIDAR

Next Previous
Trial Profile

Predictors of Antidepressant Treatment Response: The Emory CIDAR

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duloxetine (Primary) ; Escitalopram (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms PReDICT

Most Recent Events

  • 07 Mar 2025 Results assessing metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive-Behavioral Therapy (CBT) in 163 treatment-naive outpatients with major depressive disorder, published in the Journal of Affective Disorders.
  • 16 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 09 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top